Compare HOVR & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | PYPD |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Canada | Israel |
| Employees | 30 | 75 |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.6M | 85.1M |
| IPO Year | N/A | 2014 |
| Metric | HOVR | PYPD |
|---|---|---|
| Price | $2.34 | $4.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $10.33 | ★ $12.25 |
| AVG Volume (30 Days) | ★ 2.0M | 59.6K |
| Earning Date | 04-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $2.44 |
| 52 Week High | $4.18 | $5.12 |
| Indicator | HOVR | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 58.47 |
| Support Level | $1.70 | $4.15 |
| Resistance Level | $2.50 | $5.05 |
| Average True Range (ATR) | 0.29 | 0.22 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 38.47 | 87.10 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.